Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
Lam VK, Zhang J, Wu CC, Tran HT, Li L, Diao L, Wang J, Rinsurongkawong W, Raymond VM, Lanman RB, Lewis J, Roarty EB, Roth J, Swisher S, Lee JJ, Gibbons DL, Papadimitrakopoulou VA, Heymach JV. Lam VK, et al. Among authors: papadimitrakopoulou va. J Thorac Oncol. 2021 Apr;16(4):601-609. doi: 10.1016/j.jtho.2020.12.011. Epub 2020 Dec 31. J Thorac Oncol. 2021. PMID: 33388476 Free PMC article.
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, Pisters KM, Shin DM, Papadimitrakopoulou VA, Kurie JM, Blumenschein G Jr, Kies MS, Zinner R, Jung MS, Lu R, Lee JJ, Munden RF, Hong WK, Lee JS. Herbst RS, et al. Among authors: papadimitrakopoulou va. Cancer. 2002 Jul 15;95(2):340-53. doi: 10.1002/cncr.10629. Cancer. 2002. PMID: 12124835 Free article. Clinical Trial.
Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy.
Swisher SG, Roth JA, Komaki R, Gu J, Lee JJ, Hicks M, Ro JY, Hong WK, Merritt JA, Ahrar K, Atkinson NE, Correa AM, Dolormente M, Dreiling L, El-Naggar AK, Fossella F, Francisco R, Glisson B, Grammer S, Herbst R, Huaringa A, Kemp B, Khuri FR, Kurie JM, Liao Z, McDonnell TJ, Morice R, Morello F, Munden R, Papadimitrakopoulou V, Pisters KM, Putnam JB Jr, Sarabia AJ, Shelton T, Stevens C, Shin DM, Smythe WR, Vaporciyan AA, Walsh GL, Yin M. Swisher SG, et al. Clin Cancer Res. 2003 Jan;9(1):93-101. Clin Cancer Res. 2003. PMID: 12538456 Clinical Trial.
Akt activation correlates with adverse outcome in tongue cancer.
Massarelli E, Liu DD, Lee JJ, El-Naggar AK, Lo Muzio L, Staibano S, De Placido S, Myers JN, Papadimitrakopoulou VA. Massarelli E, et al. Among authors: papadimitrakopoulou va. Cancer. 2005 Dec 1;104(11):2430-6. doi: 10.1002/cncr.21476. Cancer. 2005. PMID: 16245318 Free article.
Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer.
Zinner RG, Fossella FV, Gladish GW, Glisson BS, Blumenschein GR Jr, Papadimitrakopoulou VA, Pisters KM, Kim ES, Oh YW, Peeples BO, Ye Z, Curiel RE, Obasaju CK, Hong WK, Herbst RS. Zinner RG, et al. Among authors: papadimitrakopoulou va. Cancer. 2005 Dec 1;104(11):2449-56. doi: 10.1002/cncr.21480. Cancer. 2005. PMID: 16258975 Free article. Clinical Trial.
Fenretinide activity in retinoid-resistant oral leukoplakia.
Lippman SM, Lee JJ, Martin JW, El-Naggar AK, Xu X, Shin DM, Thomas M, Mao L, Fritsche HA Jr, Zhou X, Papadimitrakopoulou V, Khuri FR, Tran H, Clayman GL, Hittelman WN, Hong WK, Lotan R. Lippman SM, et al. Clin Cancer Res. 2006 May 15;12(10):3109-14. doi: 10.1158/1078-0432.CCR-05-2636. Clin Cancer Res. 2006. PMID: 16707609 Clinical Trial.
159 results